ASH 2020: Results of a phase II study investigating ibrutinib combined with venetoclax for treatment of relapsed chronic lymphocytic leukemia.
Home / Resource Library / Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial